Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESIRE MS: Anti-CD20 Maintenance versus De-escalation in Relapsing-Remitting Multiple Sclerosis
2024-513292-40-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab, ocrelizumab, ofatumumab, dimethyl fumarate, diroximel fumarate and 4 more in multiple sclerosis (MS) (2 arms), sponsored by Centre Hospitalier Universitaire de Montpellier. Primary endpoint: No disease activity at 36 months. Planned start Apr 2025; status: authorised.
02
Drugs
rituximabocrelizumabofatumumabdimethyl fumaratediroximel fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-513292-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513292-40-00.